Allogene Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -19.7% | -19.7% | -17.3% |
| FY2022 | -51.0% | -51.0% | -41.4% |
| FY2023 | -63.9% | -63.9% | -50.9% |
| FY2024 | -61.0% | -61.0% | -46.9% |
| FY2025 | -65.3% | -65.3% | -45.9% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -19.7% | -19.7% | -17.3% |
| FY2022 | -51.0% | -51.0% | -41.4% |
| FY2023 | -63.9% | -63.9% | -50.9% |
| FY2024 | -61.0% | -61.0% | -46.9% |
| FY2025 | -65.3% | -65.3% | -45.9% |